American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
Suzetrigine: A novel selective sodium channel inhibitor for pain.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Courtney Denise, Potru Sudheer, Mathew Paige
Аннотация
PURPOSE: To explore suzetrigine, a novel voltage-gated sodium channel inhibitor for pain management.
SUMMARY: Suzetrigine is a first-in-class, oral peripheral sodium channel inhibitor that selectively targets Nav1.8 channels and was recently approved for the treatment of moderate to severe acute pain. In phase 3 trials, suzetrigine demonstrated superior efficacy to placebo in reducing pain intensity after surgery and was generally well tolerated. Studies for nonacute pain indications, including diabetic peripheral neuropathy and painful lumbosacral radiculopathy, are in progress.
CONCLUSION: Suzetrigine represents an advancement in pain management as a nonopioid alternative for pain with potentially lower abuse risk and potentially fewer serious adverse effects when compared to opioids. While initial results are promising, further research is needed to establish its long-term safety and efficacy for various painful conditions. Research will continue in the area of analgesics that selectivity inhibit peripheral sodium channels.
SUMMARY: Suzetrigine is a first-in-class, oral peripheral sodium channel inhibitor that selectively targets Nav1.8 channels and was recently approved for the treatment of moderate to severe acute pain. In phase 3 trials, suzetrigine demonstrated superior efficacy to placebo in reducing pain intensity after surgery and was generally well tolerated. Studies for nonacute pain indications, including diabetic peripheral neuropathy and painful lumbosacral radiculopathy, are in progress.
CONCLUSION: Suzetrigine represents an advancement in pain management as a nonopioid alternative for pain with potentially lower abuse risk and potentially fewer serious adverse effects when compared to opioids. While initial results are promising, further research is needed to establish its long-term safety and efficacy for various painful conditions. Research will continue in the area of analgesics that selectivity inhibit peripheral sodium channels.